GlaxoSmithKline Pharmaceuticals received a Final Order from TDS Authority INT Tax Circle 2(3)(2) with ₹2.01 Crore demand liability.
The demand covers TDS default u/s 201 for AY 2020-21, comprising ₹1.11 Cr TDS and ₹0.90 Cr interest.
Company stated no financial statement impact as it plans to contest the order by filing an appeal before the appellate authority.